Avirmax CMC Inc. based in the SF Bay Area, is dedicated to develop the state-of-the-art technologies to address current challenges in the recombinant adeno-associated virus (rAAV) bioprocess development and manufacturing using its proprietary rAAV production platforms based on the Bac-to-AAV and HEK293 technologies to provide rAAV services from DNA Sequences into final Gene Therapy Products for Clinical Investigation.